New opportunities for the management of cancer-related bone complications

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 5 SUPPL. 11, 2009, Pages 4-30

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; DOXORUBICIN; ESTROGEN; ETIDRONIC ACID; GONADORELIN AGONIST; GOSERELIN; IBANDRONIC ACID; LETROZOLE; LEUPRORELIN; MITOXANTRONE; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; PREDNISONE; RALOXIFENE; RHENIUM 186; RISEDRONIC ACID; STRONTIUM 89; TAMOXIFEN; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ALBUMINURIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE DISEASE; BONE MARROW METASTASIS; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; BONE REMODELING; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INDUCED BONE LOSS; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; HEALTH CARE COST; HUMAN; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY FUNCTION; LIVER METASTASIS; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NERVE COMPRESSION; NONHUMAN; ORTHOPEDIC SURGERY; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PROSTATE CANCER; RADIODIAGNOSIS; RISK ASSESSMENT; SIDE EFFECT; SPINAL CORD COMPRESSION; UNSPECIFIED SIDE EFFECT; UREMIA; VERTEBRA FRACTURE;

EID: 66749184679     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (125)

1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997 October 15;80(8 Suppl):1588-1594.
2. Theriault RL. Pathophysiology and implications of cancer treatment-induced bone loss. Oncology (Williston Park). 2004 May;18(5 Suppl 3):11-15.
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002 August;2(8):584-593.
4. Vessella RL, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res. 2006 October 15;12(20 Pt 2):6285s-6290s.
5. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000 March 1;88(5):1082-1090.
6. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003 October 15;98(8):1735-1744.
7. Aapro MS. Management of bisphosphonate treatment in clinical practice. Semin Oncol. 2007 December;34(6 Suppl 4):S28-S32.
8. Coleman RE. Emerging strategies in bone health management for the adjuvant patient. Semin Oncol. 2007 December;34(6 Suppl 4):S11-S16.
9. Lipton A. Future treatment of bone metastases. Clin Cancer Res. 2006 October 15;12(20 Pt 2):6305s-6308s.
10. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006 October 15;12(20 Pt 2):6243s-6249s.
11. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin. 2008 February 20;71-96.
12. Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005 May;23(15):3314-3321.
13. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996 December 12;335(24):1785-1791.
14. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9 (Suppl 4):14-27.
15. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002 October 2;94(19):1458-1468.
16. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004 June 2;96(11):879-882.
17. Esteve FR, Roodman GD. Pathophysiology of myeloma bone disease. Best Pract Res Clin Haematol. 2007 December;20(4):613-624.
18. Berenson JR, Hillner BE, Kyle RA et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002 September 1;20(17):3719-3736.
19. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996 February 22;334(8):488-493.
20. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998 February;16(2):593-602.
21. Eaton CL, Coleman RE. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat Rev. 2003 June;29(3):189-198.
22. Van Poznak CH. The use of bisphosphonates in patients with breast cancer. Cancer Control. 2002 November;9(6):480-489.
23. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002 September;168(3):1005-1007.
24. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007 October 15;110(8):1860-1867.
25. Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005 April;16(4):579-584.
26. McKiernan JM, Delea TE, Liss M et al. Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004 July 15;22(14S). Abstract 6057.
27. Delea TE, McKiernan J, Brandman J et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol. 2006 July;1(6):571-576.
28. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004 April 15;350(16):1655-1664.
29. Engleman VW, Nickols GA, Ross FP et al. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest. 1997 May 1;99(9):2284-2292.
30. Oshima T, Abe M, Asano J et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005 November 1;106(9): 3160-3165.
31. Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003 December 25;349(26):2483-2494.
32. Giuliani N, Morandi F, Tagliaferri S et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007 July 1;110(1):334-338.
33. Giuliani N, Colla S, Morandi F et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005 October 1;106(7):2472-2483.
34. Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med. 2008 March 6;10:e7.
35. D'Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M. Guidelines for the use of imaging in the management of myeloma. Br J Haematol. 2007 April;137(1): 49-63.
36. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. V.1.2009. National Comprehensive Cancer Network 2009. Available at: http://www.nccn.org/professionals/ physician_gls/PDF/prostate.pdf.
37. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006 February;132(4):410-451.
38. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005 August 1;23(22):4925-4935.
39. Berenson JR, Rajdev L, Broder M. Treatment strategies for skeletal complications of cancer. Cancer Biol Ther. 2006 September;5(9):1074-1077.
40. Bartels RH, van der Linden YM, van der Graaf WT. Spinal extradural metastasis: review of current treatment options. CA Cancer J Clin. 2008 July;58(4): 245-259.
41. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol. 2004 May;2(3):205-213.
42. Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther. 2006 April 1;3(3):143-153.
43. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer. 2004 June 1;11(2):207-224.
44. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999 March;17(3):846-854.
45. Rosen LS, Gordon DH, Dugan W, Jr. et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004 January 1;100(1):36-43.
46. Coleman RE. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. Am J Clin Oncol. 2002 December;25(6 Suppl 1):S25-S31.
47. Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003 September 3;95(17):1300-1311.
48. Ernst DS, Tannock IF, Winquist EW et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003 September 1;21(17):3335-3342.
49. Lipton A, Small E, Saad F et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002;20(Suppl 2):45-54.
50. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 November 1;21(21):4042-4057.
51. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001 September;7(5):377-387.
52. Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008 March;19(3):420-432.
53. Kyle RA, Yee GC, Somerfield MR et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007 June 10;25(17):2464-2472.
54. Diel IJ, Solomayer EF, Bastert G. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer. 2000 June 15;88(12 Suppl):3080-3088.
55. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004 September;114(5):623-633.
56. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer. 2005 January;113(3):364-371.
57. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004 July 1;10(13):4559-4567.
58. Daubine F, Le GC, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007 February 21;99(4):322-330.
59. Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002 August 1;20(15):3219-3224.
60. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001 January 1;19(1):10-17.
61. Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998 August 6;339(6):357-363.
62. Diel IJ, Jaschke A, Solomayer EF et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008 December;19(12):2007-2011.
63. Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8(2):R13.
64. Lin A, Park J, Melisko M et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Presented at the 2007 San Antonio Breast Cancer Symposium. Abstract 510.
65. Brufsky A, Bundred N, Coleman R et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008 May;13(5):503-514.
66. Eidtmann H, Bundred NJ, DeBoer R et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Presented at the San Antonio Breast Cancer Symposium. Abstract 44.
67. Gnant M, Mlineritsch B, Schippinger W et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. J Clin Oncol. 2008 May 20;26(May 20 suppl):Abstract LBA4.
68. Smith MR. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J Urol. 2003 December;170(6 Pt 2):S55-S57.
69. Smith MR. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Urol Oncol. 2008 July;26(4):420-425.
70. Paterson AH. The role of bisphosphonates in early breast cancer. Oncologist. 2006;11(Suppl 1):13-19.
71. Coleman R, Thorpe H, Cameron D et al. Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy: first safety data from the AZURE trial (BIG01/04). Presented at the 2006 San Antonio Breast Cancer Symposium. Abstract 2080.
72. Wirth M. Effectiveness of zoledronic acid for the prevention of bone metastases in high-risk prostate cancer patients: Study design and current enrollment of the Zoledronic Acid European Study (ZEUS). Presented at the American Society of Clinical Oncology 2007 Prostate Cancer Symposium. Abstract 274.
73. Khosla S, Melton LJ, III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001 August;86(8):3555-3561.
74. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
75. Melton LJ, III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res. 1992 September; 7(9):1005-1010.
76. Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006 November;11(10):1121-1131.
77. Aapro MS. Long-term implications of bone loss in breast cancer. Breast. 2004 December;13 (Suppl 1):S29-37.:S29-S37.
78. Hadji P, Bundred N. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Semin Oncol. 2007 December;34(6 Suppl 4): S4-S10.
79. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 January 1;365(9453):60-62.
80. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008 January;9(1):45-53.
81. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 February 10;25(5):486-492.
82. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 2006 November;98(5):973-978.
83. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002 August;87(8):3656-3661.
84. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005 January 13;352(2): 154-164.
85. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005 November 1;23(31):7897-7903.
86. Kanis JA, Borgstrom F, De Laet C et al. Assessment of fracture risk. Osteoporos Int. 2005 June;16(6):581-589.
87. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998 March 12;338(11):736-746.
88. Bone and Cancer Foundation. Vitamin D deficiency: information for cancer patients. Bone and Cancer Foundation 2008; Available at: http://www.boneandcancerfoundation.org/Vitamin_D_Booklet.pdf. Accessed November 6, 2008.
89. Greenspan SL, Brufsky A, Lembersky BC et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol. 2008 June 1;26(16):2644-2652.
90. Powles TJ, McCloskey E, Paterson AH et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998 May 6;90(9):704-708.
91. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007 March 1;25(7):820-828.
92. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008 September;9(9):840-849.
93. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007 March 1;25(7):829-836.
94. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001 September 27;345(13):948-955.
95. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007 March;146(6):416-424.
96. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003 June;169(6):2008-2012.
97. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006 September;176(3):972-978.
98. Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007 March 20;25(9):1038-1042.
99. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004 August;89(8): 3841-3846.
100. Smith MR, Malkowicz SB, Chu F et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008 January; 179(1):152-155.
101. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005 January;10(1):52-62.
102. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007 October;22(10):1479-1491.
103. Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008 June;23(6):826-836.
104. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16; 144(10):753-761.
105. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006 February;24(6):945-952.
106. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, III, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008 August; 26(24):4037-4038.
107. Sung EC, Chan SM, Sakurai K, Chung E. Osteonecrosis of the maxilla as a complication to chemotherapy: a case report. Spec Care Dentist. 2002 July;22(4):142-146.
108. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003 September;61(9):1104-1107.
109. Badros A, Evangelos T, Goloubeva O et al. Long-term follow-up of multiple myeloma (mm) patients (pts) with osteonecrosis of the jaw (ONJ). Blood. 2007 November 16;110(11):Abstract 3519.
110. Lipton A, Steger GG, Figueroa J et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007 October 1;25(28):4431-4437.
111. Body JJ, Facon T, Coleman RE et al. A study of the biological receptor activator of nuclear factor-{kappa}B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006 February 15;12(4):1221-1228.
112. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther. 2007;9(Suppl 1):S7.
113. Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008 October 20;26(30):4875-4882.
114. McClung M, Bone H, Cosman F et al. A randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24-month results. Presented at the 2008 American Society for Bone and Mineral Research 30th Annual Meeting. Abstract 1291.
115. Jensen AB, Olmeo N, Wynne C et al. Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial. J Clin Oncol. 2008 May 20;26(May 20 suppl):Abstract 1023.
116. Smith MR, Nelson JB. Future therapies in hormone-refractory prostate cancer. Urology. 2005 May;65(5 Suppl):9-16.
117. Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003 February 15;21(4):679-689.
118. Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007 November 1;110(9):1959-1966.
119. Nelson JB, Love W, Chin JL et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008 November 1;113(9):2478-2487.
120. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006 August 1;107(3):530-535.
121. Marzia M, Sims NA, Voit S et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol. 2000 October 16;151(2): 311-320.
122. Rucci N, Susa M, Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem. 2008 April;8(3):342-349.
123. Bandyopadhyay A, Agyin JK, Wang L et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res. 2006 July 1;66(13):6714-6721.
124. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD, Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007 March 1;109(5):2106-2111.
125. Roodman GD. Bone building with bortezomib. J Clin Invest. 2008 February; 118(2):462-464.